Breast Cancer Trials

S1207

S1207 – Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-positive and HER2/Neu negative breast cancer.

1. What type of cancer? What stage?
   1. Early stage breast cancer – Stage 1, 2, and 3
2. Who is eligible?
   1. Women who are ER/PR+ but Her2-
3. How will I be treated?
   1. Women may also receive Everolimus – an mTOR inhibitor

A5481082

A5481082 – Palbociclib in hormone receptor positive advanced breast cancer: a prospective multi center non-interventional study

1. What type of cancer? What stage?
   1. Triple negative breast cancer
2. Who is eligible?
   1. Women with inoperable or metastatic disease
3. How will I be treated?
   1. Women may also receive palcociclib (Ibrance), which is used to treat ER+ breast cancer.

For physicians: more information about this specific trial at clinicaltrials.gov.